Why Is ACADIA PHARMACEUTICA (ACAD) Stock Down Today?

ACADIA Pharmaceuticals stock fell 9.79% to $22.94 in morning trading on Monday, marking a sharp decline driven by disappointing clinical trial results. The company announced top-line data from its Phase II RADIANT study of remlifanserin in Alzheimer’s disease psychosis, which narrowly missed its primary endpoint with a p-value of 0.0603. The stock gapped down from $25.43 to $25.15 and fell further to a session low of $20.00 before stabilizing near $23. Volume was elevated at 3.3 million shares, more than double the 3-month daily average.

What Happened

The RADIANT study results were the catalyst for the sell-off. While the trial showed nominal significance on the CGI-S-ADP secondary endpoint, the failure to meet the primary SAPS-H+D endpoint raised concerns about the drug’s potential. Analysts responded swiftly. Goldman Sachs and BMO both downgraded or reduced price targets, with BMO cutting its target and Goldman Sachs reiterating its Sell rating. Citi also lowered its price target to $33 from $40. Meanwhile, Seeking Alpha analysts expressed skepticism, estimating a 25% probability of success for remlifanserin in future trials due to efficacy and design concerns.

Insiders have also been selling. Over the past 90 days, three insider sales totaling $1.3 million were reported, including transactions by the CFO and head of research and development. Congressional activity included a single sell by former President Donald J. Trump in late July.

What The Data Shows

The stock has fallen 13% over the past eight sessions and is now trading near its 52-week low of $19.69. It printed nine fresh 52-week lows on Monday. The intraday session showed a rapid deterioration in sentiment, with the stock falling from a high of $25.23 to a low of $20.00 within the first hour of trading. The 30-day average sentiment score has declined from 44 to 40 over the past week. The stock’s fundamentals remain mixed, with a strong net margin of 33.4% and a P/E of 11.7, but its recent performance has been volatile.

What To Watch

The next key event for ACAD is the broader analyst coverage and potential follow-up guidance from the company. Investors will be watching for any updates on the path to Phase III trials for remlifanserin.